Americans shelled out an estimated $71 billion for weight-loss drugs in 2023 - that is as much as the U.S. government ...

"With the FDA announcing the resolution of shortages for Semaglutide (Wegovy, Ozempic) and Tirzepatide (Zepbound, Mounjaro), compounding pharmacies must halt production of these medications. This ...

But this doesn't negate the drugs' potential downsides, one of which has doctors urging patients to "proceed with caution" ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Novo Nordisk argues Medicare should negotiate the price for six of its insulin products separately, though they contain the ...

The latest discovery in obesity medicine will be available in less invasive creams and patches, known as transdermal drug ...

Several hundred units of counterfeit Ozempic (semaglutide 1mg injection) were seized by the Food and Drug Administration.

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Novo Nordisk has awarded a 50 million kroner ($7.6M) grant to the University of Copenhagen to develop less processed ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

GLP-1 antidiabetic drugs, which reduce body mass by 25%, impact the processed food or alcohol industry and force fashion and insurance to transform. The unwanted side effect in medicine is any ...